A Study to Assess PK, Safety and Efficacy of HSK47977 Tablets in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma
A Phase I Clinical Study to Evaluate the Safety, Efficacy, and PK/PD Characteristics of HSK47977 Tablets in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Yunfen Li
- Phone Number: (+86)18108214952
- Email: liyunfen@haisco.com
Study Locations
-
-
-
Tianjin, China
- Recruiting
- Chinese Academy of Medical Sciences Blood Diseases Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Voluntarily sign the informed consent form.
- Age ≥18 years, with no gender restriction.
- Pathologically confirmed patients with relapsed/refractory Non-Hodgkin Lymphoma (rrNHL).
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 2.
- Expected survival >3 months.
- Presence of measurable lesions.
- Adequate organ function.
- Agreement to undergo pathological tissue biopsy.
- Subjects of childbearing potential must agree to comply with the contraceptive requirements of the study.
- No pregnancy plans from screening until at least 3 months after the last dose of the study drug, and voluntary use of effective contraceptive measures.
Exclusion Criteria:
- Concurrent presence of other severe, unstable diseases/conditions that, in the investigator's judgment, make participation in this study unsuitable.
- History of or current severe cardiovascular disease.
- Poorly controlled blood pressure during the screening period.
- Laboratory abnormalities identified by the investigator that may pose a risk to the subject's safety.
- Electrocardiogram abnormalities determined by the investigator as potentially posing a risk to the subject's safety.
- History of allergies to the investigational drug or its excipients.
- Inability to discontinue prohibited medications as specified in the protocol during the screening period and throughout the entire study duration.
- Any other conditions that may increase subject risk or interfere with the trial results.
- Any other situations where the investigator deems the subject unsuitable for participation.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Phase Ia (Dose Escalation Part): HSK47977
Phase 1a (Dose Escalation Part): dose escalation of HSK47977 at various dose levels
|
Taken orally once daily.
|
|
Experimental: Phase Ia (Extension Part): HSK47977
Phase 1a (Part B): dose extention of HSK47977 at certain dose levels
|
Taken orally once daily.
|
|
Experimental: Phase Ib: HSK47977
Phase 1b: dose expansion for HSK47977 at dose of RP2D(Recommended Phase II Dose)
|
Taken orally once daily.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Maximum tolerated dose (MTD)
Time Frame: Within first 28 days of treatment
|
Highest dose level at which under 33% of patients in a cohort experience DLT(dose limiting toxicity)
|
Within first 28 days of treatment
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- HSK47977-101
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.